Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2
Hybridoma Technology01:31

Hybridoma Technology

18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026
Same author

[<sup>18</sup>F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Haematologica·2026
Same author

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Cell stem cell·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Med (New York, N.Y.)·2026
Same author

Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple Myeloma.

Cancer management and research·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

マルチプルミエロマ (多発性ミエロマ)

Christoph Röllig1, Stefan Knop2, Martin Bornhäuser1

  • 1Medizinische Klinik und Poliklinik I, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Lancet (London, England)
|December 27, 2014
PubMed
まとめ
この要約は機械生成です。

新種の治療法により,多発性骨髄腫患者の治療結果が改善されています. 研究は,治療の効果と生活の質のバランスを取ることに焦点を当て,このプラズマ細胞悪性腫瘍の長期的な寛解と潜在的な治癒を目指しています.

さらに関連する動画

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

関連する実験動画

Last Updated: Apr 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

科学分野:

  • 血液学 ヘマトロジ
  • 腫瘍学 腫瘍学
  • 免疫学 免疫学とは

背景:

  • 多発性骨髄腫は,クローナルプラズマ細胞の増殖とモノクローナル免疫グロブリン分泌を含む骨髄の悪性腫瘍です.
  • 疾患の進行と治療抵抗における骨髄のマイクロ環境の役割を理解することは,治療の進歩を促しています.

研究 の 目的:

  • 多発性骨髄腫の治療における最近の進歩をレビューする.
  • 新薬とサポートケアが患者のアウトカムに与える影響を強調する.
  • 現在の臨床研究方向と将来の治療希望を概説する.

主な方法:

  • 多発性骨髄腫の現在の臨床研究と治療戦略のレビュー.
  • 新薬 (プロテアゾーム阻害剤,免疫調節薬) の併用療法における役割の分析.
  • オートログの幹細胞移植とサポートケアにおける進歩を考慮する.

主要な成果:

  • 既存の治療法と組み合わせた新しい治療薬は,反応率と生存率を大幅に改善しました.
  • 腫瘍の微小環境の理解が深まったことで,標的治療法の開発が容易になりました.
  • 現在の研究は,治療順序の最適化,生活の質,長期的な寛解の達成に焦点を当てています.

結論:

  • 新薬や幹細胞移植を含むマルチモダルの治療戦略は,多発性骨髄腫の予後を大幅に改善しています.
  • 進行中の臨床試験と新しい治療法の有望なパイプラインは,継続的な進歩への希望を提供します.
  • 将来の研究は,患者の生活の質を優先しながら,長期的な寛解と潜在的な治癒を達成することを目指しています.